Insight Genetics, the Nashville, Tenn.-based molecular laboratory that focuses on oncology diagnostics, has launched a new laboratory to process assays. The opening of the 2,750-square-foot Insight Molecular Labs was announced last month. Also based in Nashville, the CLIA-certified facility will offer a mixture of commonplace molecular tests such as KRAS, BRAF, and EGFR gene mutation analysis, as well as Insight’s own proprietary products. The company had been operating a smaller, non-CLIA-certified laboratory. The new facility was about a year in the making, according to company spokesperson Samantha Fiala, who noted that it was ramped up as business has developed. The most significant test offered by Insight Genetics is the Insight ALK Screen, a qPCR test that assays fusions in the ALK gene. Such fusions tend to be responsive to kinase-inhibiting drugs. It also offers a more intensive variation of the test to determine a tumor’s level of resistance to kinase-inhibiting drugs. “The laboratory is a natural extension of Insight Genetics’ work and will help us leverage our scientific expertise and specialized experience in resistance detection and monitoring to assist physicians in making therapy decisions and help identify patients for clinical trials,” said Eric Dahlhauser, Insight Genetics’s chief executive officer. “We […]
Insight Genetics, the Nashville, Tenn.-based molecular laboratory that focuses on oncology diagnostics, has launched a new laboratory to process assays.
The opening of the 2,750-square-foot Insight Molecular Labs was announced last month. Also based in Nashville, the CLIA-certified facility will offer a mixture of commonplace molecular tests such as KRAS, BRAF, and EGFR gene mutation analysis, as well as Insight’s own proprietary products.
The company had been operating a smaller, non-CLIA-certified laboratory. The new facility was about a year in the making, according to company spokesperson Samantha Fiala, who noted that it was ramped up as business has developed.
The most significant test offered by Insight Genetics is the Insight ALK Screen, a qPCR test that assays fusions in the ALK gene. Such fusions tend to be responsive to kinase-inhibiting drugs. It also offers a more intensive variation of the test to determine a tumor’s level of resistance to kinase-inhibiting drugs.
“The laboratory is a natural extension of Insight Genetics’ work and will help us leverage our scientific expertise and specialized experience in resistance detection and monitoring to assist physicians in making therapy decisions and help identify patients for clinical trials,” said Eric Dahlhauser, Insight Genetics’s chief executive officer. “We look forward to the future of Insight Molecular Labs and the contributions it will make to enhancing drug development and patient care.”
The new lab recently hired an associate director of business development to spur sales of tests, according to Fiala.
Projected test volumes for the new lab were not immediately available.
Takeaway: Molecular specialty labs such as Insight Genetics are continuing to ramp up their infrastructure to process their own proprietary tests.
